Ticker

The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).

Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) --  Adlai Nortye Ltd.

Adlai Nortye (NASDAQ: ANL - Get Free Report) is projected to announce its Q2 2026 resultson Thursday, August 6th. Analysts expect Adlai Nortye to announce earnings of ($0.1333) per share and revenue of $3.95 million for the quarter. Individuals are encouraged to explore the company's upcoming Q2 2026 earning overview page for the latest details on

First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J.

First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD and QW arms are now enrolling SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.